Evidence map›Paper›PMID 30688049›Full record

ArticleDiabetes & metabolism journal2019

Myricetin Protects Against High Glucose-Induced β-Cell Apoptosis by Attenuating Endoplasmic Reticulum Stress via Inactivation of Cyclin-Dependent Kinase 5.

Udayakumar Karunakaran, Suma Elumalai, Jun Sung Moon, Jae Han Jeon, Nam Doo Kim, Keun Gyu Park, Kyu Chang Won, Jaechan Leem, In Kyu Lee

Open access · goldAbstract read
In one paragraph

Article in Diabetes & metabolism journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Mitigation of Hepatic and Pancreatic Injury byFood science & nutrition · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Profiling of secondary metabolite and evaluation of anti-diabetic potency ofSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Udayakumar KarunakaranDepartment of Biomedical Science, Graduate School of Medicine, Kyungpook National University, Daegu, Korea.
Suma ElumalaiInstitute of Medical Science, Yeungnam University College of Medicine, Daegu, Korea.
Jun Sung MoonDepartment of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Jae Han JeonDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.
Nam Doo KimNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Korea.
Keun Gyu ParkDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.
Kyu Chang WonDepartment of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Jaechan LeemDepartment of Immunology, School of Medicine, Catholic University of Daegu, Daegu, Korea. jcim@cu.ac.kr.ORCID 0000-0003-2329-4374
In Kyu LeeDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea. leei@knu.ac.kr.ORCID 0000-0001-7908-8129
Kyungpook National University Hospital · KRYeungnam University CollegeDaegu Catholic University · KRDaegu-Gyeongbuk Medical Innovation Foundation · KRKyungpook National University · KR

Funding

KNUNRF 2016R1E1A2020567
6 · The paper itself

Abstract

backgroundChronic hyperglycemia has deleterious effects on pancreatic β-cell function and turnover. Recent studies support the view that cyclin-dependent kinase 5 (CDK5) plays a role in β-cell failure under hyperglycemic conditions. However, little is known about how CDK5 impair β-cell function. Myricetin, a natural flavonoid, has therapeutic potential for the treatment of type 2 diabetes mellitus. In this study, we examined the effect of myricetin on high glucose (HG)-induced β-cell apoptosis and explored the relationship between myricetin and CDK5.

methodsTo address this question, we subjected INS-1 cells and isolated rat islets to HG conditions (30 mM) in the presence or absence of myricetin. Docking studies were conducted to validate the interaction between myricetin and CDK5. Gene expression and protein levels of endoplasmic reticulum (ER) stress markers were measured by real-time reverse transcription polymerase chain reaction and Western blot analysis.

resultsActivation of CDK5 in response to HG coupled with the induction of ER stress via the down regulation of sarcoendoplasmic reticulum calcium ATPase 2b (

conclusionMyricetin protects the β-cells against HG-induced apoptosis by inhibiting ER stress, possibly through inactivation of CDK5 and consequent upregulation of PDX1 and SERCA2b.

Indexed as

AnimalsApoptosisCell Line, TumorCyclin-Dependent Kinase 5Endoplasmic Reticulum StressFlavonoidsGlucoseHomeodomain ProteinsInsulinInsulin-Secreting CellsMembrane Potential, MitochondrialMolecular Docking SimulationProtective AgentsRatsReactive Oxygen SpeciesSarcoplasmic Reticulum Calcium-Transporting ATPasesAtp2a2 protein, ratCdk5 protein, ratCyclin-Dependent Kinase 5FlavonoidsGlucoseHomeodomain ProteinsInsulinmyricetinpancreatic and duodenal homeobox 1 proteinProtective AgentsReactive Oxygen SpeciesSarcoplasmic Reticulum Calcium-Transporting ATPasesTrans-ActivatorsApoptosisCyclin-dependent kinase 5Endoplasmic reticulum stressInsulin-secreting cellsMyricetin

Identifiers

PMID30688049
PMCPMC6470101
OpenAlexW2908828620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.